Presbyopia Market

DelveInsight’s ‘Presbyopia - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Presbyopia market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted 7MM Presbyopia market size from 2019 to 2032. The Report also covers current Presbyopia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Presbyopia Disease Understanding and Treatment Algorithm

Presbyopia Overview

Presbyopia is a normal part of aging wherein your eyes gradually lose the ability to see things up close. The term “presbyopia” comes from a Greek word that means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.

 

It is mostly due to age-related changes that the proteins within the lens of the eye become thicker, harder, and less flexible. This loss of flexibility affects the lens's ability to refract light rays which, in turn, affects the eye's capacity to focus. Age is the major risk factor for the development of presbyopia along with factors like trauma, systemic disease, cardiovascular disease, or a drug side effect. According to type, Presbyopia can be classified into incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia

 

Initial symptoms include difficulties with prolonged close-up work along with tiring of the eyes. Other common symptoms are delays in focusing at near or distance, ocular discomfort, headache, asthenopia, squinting, fatigue or drowsiness from near work, increased working distance, need for brighter light for reading, and diplopia. This may progress to blurred vision when looking at objects close up and to headaches and eye strain when attempting close work.

 

Presbyopia Diagnosis

A basic and comprehensive examination of the eye with a series of different tests is necessary to diagnose presbyopia. The ophthalmologist examines the retina and conducts muscle integrity, refraction, slit-lamp, visual field, and visual acuity tests. These will help to ascertain the condition. Eye drops used during this process to dilate the pupils will cause patients to experience increased sensitivity to light in the few hours following the examinations.

 

With the help of an ophthalmoscope, the specialist can evaluate the retina, optic disk, and choroid (i.e. a layer of blood vessels responsible for providing nourishment to the retina). A muscle integrity test is done with a moving object, and the ability to follow this object is evaluated. Refractive tests assess how well light waves are bent as they go through the cornea and the lens and the results of these tests help to determine which lens prescription will be needed. Presbyopia cannot be prevented as it is an inevitable part of aging.

Continued in the report…..

 

Presbyopia Treatment

The goal of treatment is to compensate for the inability of your eyes to focus on nearby objects. Treatment includes wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia. Most clinical management of presbyopia includes nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. The commonly used off-label ophthalmic drops have pilocarpine, carbachol, aceclidine, brimonidine, and nepafenac as their main ingredient. They target the ciliary muscles and change the pupil size and elasticity thereby improving the near vision. Recently the US FDA approved Vuity developed by AbbVie for the treatment of presbyopia in adults.

Continued in the report…..

Presbyopia Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Presbyopia, total diagnosed cases of Presbyopia, total age-specific cases of Presbyopia, gender-specific cases of Presbyopia, and severity-specific cases of Presbyopia scenario of Presbyopia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • Total prevalent cases of Presbyopia in the 7MM were found to be 289,136,235 cases in 2021. These cases are expected to change by 2032 at a CAGR of 1.4% during the study period (2019–2032).
  • Among 7MM, the United States has the highest number of prevalent cases of Presbyopia with 118,346,762 cases in 2021.
  • Assessments as per DelveInsight’s analysts show that in 2021, in the United States, the severity-specific cases of Presbyopia were 20,301,021 and 81,204,086 cases for mild and moderate to severe cases, respectively which are expected to rise significantly by 2032.
  • In the US, the total age-specific cases of Presbyopia were 28,859,295, 33,190,032, 24,012,555, and  15,443,224 cases for the age group less than 60 years, 60–69 years, 70–79 years, and ≥80 years respectively, in the year 2021. These cases are expected to rise significantly by 2032.
  • In EU-5, Germany had the highest prevalent population of Presbyopia with 36,822,212 cases, followed by Italy with 27,683,651 cases in 2021. On the other hand, Spain had the lowest prevalent population for 2021.
  • In 2021, Japan had 34,568,372 total prevalent cases of Presbyopia.

Country-Wise Presbyopia Epidemiology

The epidemiology segment also provides the Presbyopia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Presbyopia Drug Chapters

The drug chapter segment of the Presbyopia report encloses the detailed analysis of Presbyopia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

 

Presbyopia Marketed Drugs

 

Vuity: AbbVie

Vuity (AGN-190584), developed by Allergan (which was acquired by AbbVie), is a miotic 1.25% pilocarpine hydrochloride ophthalmic solution for the treatment of presbyopia in adults. It is a topical, once-daily drop delivered by a proprietary vehicle that uses PhAST technology for rapid adjustment to the physiologic pH of the tear film. It is the first and only FDA-approved eye drop to treat presbyopia. Based on the recently announced Phase III Virgo trial results, AbbVie plans to submit a supplemental New Drug Application to the US FDA in the second quarter of 2022 for an optional twice-daily administration of Vuity for the treatment of presbyopia in adults.

Product’s detail in the report…

 

Presbyopia Emerging Drugs

 

MicroLine (Pilocarpine Ophthalmic): Eyenovia

MicroLine of Eyenovia is a patented micro-dosed pilocarpine formulation distributed through the Optejet dispenser of the Business. Pilocarpine works by creating a Pinhole effect, which is done by the constricting of the pupil of the eye, similar to a pinhole camera, and brings near and medium-distance objects into focus. With MicroLine, Eyenovia is trying to build an approach that can improve near vision with this micro-dosed drug. The drug is presently being evaluated in phase III (VISION -2) to determine the safety and efficacy of 2% pilocarpine ophthalmic spray in adults with presbyopia.

Product’s detail in the report…

 

CSF-1 (PresbiDrops): Orasis Pharmaceuticals

CSF-1 is a corrective eye drop being developed by Orasis Pharmaceuticals for offering an alternative to reading glasses and intrusive surgical procedures to enhance the quality of life for people with presbyopia. It is being developed to improve near visual acuity by pupil modulation, resulting in a “pinhole effect” and an increase in the depth of field, thus increasing the ability to focus on near objects. It has recently completed two Phase III trials, NEAR-1, and NEAR-2, of CSF-1 and plans on sharing the topline result in the coming months along with advancing the product towards commercialization.

Product’s detail in the report…

 

Nyxol: Ocuphire Pharma

Nyxol developed by Ocuphire Pharma is a preservative-free ophthalmic solution that contains 0.75% phentolamine (1% phentolamine mesylate), a nonselective alpha-adrenergic antagonist which inhibits the contraction of the smooth muscle of the iris. It is being developed as a single drop as well as an adjunct therapy for the treatment of presbyopia. The company plans to initiate the VEGA Phase III program in mid-2022 for investigating Nyxol alone and Nyxol with low-dose pilocarpine (LDP) as an adjunctive treatment for the potential treatment of presbyopia and expects to file NDA by 2023. Nyxol is responsible for iris dilator muscle inhibition and pilocarpine for iris sphincter muscle activation.

Product’s detail in the report…

 

UNR844 (Lipoic Acid Choline Ester): Novartis

UNR844, a lipoic acid choline ester, formerly known as EV06 is being developed by Novartis, as a potential first-in-class treatment for presbyopia. It is a decreasing agent intended to decrease the disulfide bonds that form between proteins of the lens, thereby raising the crystalline lens deformability and increasing the accommodative amplitude leading to lens softening. The company has completed Phase II trials and plans on the further development of the product to proceed with the filing for approval by 2024.

Product’s detail in the report…

List of products to be continued in the report…

Presbyopia Market Outlook

The pharmacological control of presbyopia is a desirable option for those affected by presbyopia and with an increasing near vision spectacle dependence. Current clinical management of presbyopia in the United States includes off-label treatment using miotic agents, such as pilocarpine and carbachol. One drop of pilocarpine hydrochloride ophthalmic solution 1%, 2%, or 4% (or two drops administered 5 min apart) should be applied topically in the eye(s) for the induction of miosis. Pilocarpine is also being investigated in combination with both other FDA-approved and novel ophthalmic solutions.

 

There is a high unmet need for new therapies for the treatment of presbyopia. Crossing the FDA-approval finish line first in the presbyopia drops race is Allergan (AbbVie) with Vuity (previously AGN-190584), a single-agent drop containing pilocarpine 1.25%, which was approved in October 2021. With some interesting therapies heading down the pipeline, the condition may be evolving. This would encourage reimbursement of insurance, adoption by doctors, compliance with patients, and, eventually, the genesis of a broad, untapped sector.

 

At present, some companies are conducting clinical trials that investigate new treatment options.  Key players such as Orasis Pharmaceuticals (PresbiDrops), Novartis (UNR844), Eyenovia (MicroLine), Allergan (acquired by AbbVie) (AGN-241622), Ocuphire Pharma (Nyxol), Visus therapeutics (VTI-001/Brimochol), Lenz Therapeutics (LENZ100), and several others are investigating their candidates for the management of presbyopia in the 7MM.

 

According to DelveInsight, the overall dynamics of the Presbyopia market are anticipated to change in the coming years owing to the expected launch of emerging therapies.

 

Key Findings

  • The market size of Presbyopia in seven major markets was USD 17,883 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 4.8% for the study period (2019–2032)
  • The expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the prevalent population of Presbyopia.
  • Upcoming therapies such as MicroLine, VTI-001, and others have the potential to create a significant positive shift in the Presbyopia market size.
  • The United States accounts for the largest market size of Presbyopia, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
  • Among the EU5 countries, Germany had the highest market size with USD 1,936 million in 2021.

 

The United States Market Outlook

This section provides the total Presbyopia market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total Presbyopia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Presbyopia market size and market size by therapies in Japan are provided.

Presbyopia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Presbyopia market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Presbyopia market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Presbyopia Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing, and patent details for Presbyopia emerging therapies.

Reimbursement Scenario in Presbyopia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitively and market Intelligence analysis of the Presbyopia market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Presbyopia, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Presbyopia epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Presbyopia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Presbyopia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Presbyopia market.

Report Highlights

  • The robust pipeline with novel MOA and topical ROA and increasing prevalence will positively drive the Presbyopia market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Presbyopia. The launch of emerging therapies will significantly impact the Presbyopia market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Presbyopia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Presbyopia Pipeline Analysis
  • Presbyopia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Presbyopia Report Key Strengths

  • 11-Years Forecast
  • The 7MM Coverage
  • Presbyopia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Presbyopia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Presbyopia market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Presbyopia total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Presbyopia market size during the forecast period (2022–2032)?
  • At what CAGR, the Presbyopia market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Presbyopia market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Presbyopia market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Presbyopia?
  • What is the historical Presbyopia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Presbyopia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Presbyopia?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Presbyopia during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Presbyopia along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Presbyopia in the US and Europe?
  • What are the Presbyopia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Presbyopia?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Presbyopia?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Presbyopia therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Presbyopia and their status?
  • What are the key designations that have been granted for the emerging therapies for Presbyopia?
  • What are the 7MM historical and forecasted market of Presbyopia?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Presbyopia.
  • To understand the future market competition in the Presbyopia market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Presbyopia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Presbyopia market.
  • To understand the future market competition in the Presbyopia market.

1. Key Insights

2. Report Introduction

3. Presbyopia Market Overview at a Glance

3.1. Market Share (%) Distribution of Presbyopia by Therapies in 2019

3.2. Market Share (%) Distribution of Presbyopia by Therapies in 2032

4. Presbyopia Market: Future Perspective

5. Executive Summary of Presbyopia

6. Key Events

7. Disease Background and Overview

7.1. Introduction

7.1.1. Signs and Symptoms of Presbyopia

7.1.2. Difference between Presbyopia and Hyperopia

7.1.3. Risk Factors and Causes of Presbyopia

7.1.4. Pathophysiology of Presbyopia

7.1.5. Complications of Presbyopia

8. Diagnosis of Presbyopia

8.1. Patient History

8.2. Ocular Examination

8.2.1. Visual Acuity

8.2.2. Keratometry/Topography

8.2.3. Refraction

8.2.4. Binocular Vision and Accommodation

8.3. Supplemental Testing

8.4. Eye health evaluation

8.5. Recommended eye examination frequency for pediatric patients and adults

8.6. Differential Diagnosis

9. Early Detection and Prevention of Presbyopia

10. Current Treatment Practices: Presbyopia

10.1. Treatment Algorithm of Presbyopia

10.2. Optical Correction with Spectacle Lenses

10.3. Optical Correction with Contact Lenses

10.4. Surgical options

10.4.1. Conductive keratoplasty (CK)

10.4.2. Monovision LASIK for presbyopia

10.4.3. Laser-Assisted Sub Epithelial Keratectomy (LASEK)

10.4.4. Difference between LASIK and LASEK

10.4.5. Photorefractive keratectomy (PRK)

10.4.6. IntraCor – Corneal Surgery

10.4.7. Multifocal Corneal Ablation

10.5. Corneal inlay

10.6. Lens implants

10.7. Current Pharmacological Treatment

11. Guidelines of Presbyopia

11.1. Management Strategies for Correction of Presbyopia- American Optometric Association

11.1.1. General Considerations

11.1.2. Patient Education

11.1.3. Prognosis and Follow-up

11.2. NICE guidance for corneal inlay implantation for correction of presbyopia

11.3. Management guidelines by the American Academy of Ophthalmology

11.4. Analysis of Guidelines

12. Epidemiology and Patient Population

12.1. Key Findings

12.2. Methodology of Epidemiology

12.3. Assumptions and Rationale: 7MM

12.4. Total Prevalent Cases of Presbyopia in the 7MM

12.5. The United States

12.5.1. Total Prevalent Cases of Presbyopia in the US

12.5.2. Total Diagnosed Cases of Presbyopia in the US

12.5.3. Total Age-specific Cases of Presbyopia in the US

12.5.4. Gender-specific Cases of Presbyopia in the US

12.5.5. Severity-specific Cases of Presbyopia in the US

12.6. EU-5 Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

12.6.1. Germany

12.6.1.1. Total Prevalent Cases of Presbyopia in Germany

12.6.1.2. Total Diagnosed Cases of Presbyopia in Germany

12.6.1.3. Total Age-specific Cases of Presbyopia in Germany

12.6.1.4. Gender-specific Cases of Presbyopia in Germany

12.6.1.5. Severity-specific Cases of Presbyopia in Germany

12.6.2. France

12.6.2.1. Total Prevalent Cases of Presbyopia in France

12.6.2.2. Total Diagnosed Cases of Presbyopia in France

12.6.2.3. Total Age-specific Cases of Presbyopia in France

12.6.2.4. Gender-specific Cases of Presbyopia in France

12.6.2.5. Severity-specific Cases of Presbyopia in France

12.6.3. Italy

12.6.3.1. Total Prevalent Cases of Presbyopia in Italy

12.6.3.2. Total Diagnosed Cases of Presbyopia in Italy

12.6.3.3. Total Age-specific Cases of Presbyopia in Italy

12.6.3.4. Gender-specific Cases of Presbyopia in Italy

12.6.3.5. Severity-specific Cases of Presbyopia in Italy

12.6.4. Spain

12.6.4.1. Total Prevalent Cases of Presbyopia in Spain

12.6.4.2. Total Diagnosed Cases of Presbyopia in Spain

12.6.4.3. Total Age-specific Cases of Presbyopia in Spain

12.6.4.4. Gender-specific Cases of Presbyopia in Spain

12.6.4.5. Severity-specific Cases of Presbyopia in Spain

12.6.5. The United Kingdom

12.6.5.1. Total Prevalent Cases of Presbyopia in the UK

12.6.5.2. Total Diagnosed Cases of Presbyopia in the UK

12.6.5.3. Total Age-specific Cases of Presbyopia in the UK

12.6.5.4. Gender-specific Cases of Presbyopia in the UK

12.6.5.5. Severity-specific Cases of Presbyopia in the UK

12.7. Japan

12.7.1. Total Prevalent Cases of Presbyopia in Japan

12.7.2. Total Diagnosed Cases of Presbyopia in Japan

12.7.3. Total Age-specific Cases of Presbyopia in Japan

12.7.4. Gender-specific Cases of Presbyopia in Japan

12.7.5. Severity-specific Cases of Presbyopia in Japan

13. Patient Journey

14. Key Endpoints in Presbyopia Clinical Trials

15. Marketed Drugs

15.1. Vuity: AbbVie

15.1.1. Product Description

15.1.2. Regulatory Milestones

15.1.3. Research and Development

15.1.4. Clinical Development

15.1.5. Safety and Efficacy

15.1.6. Product Profile

16. Emerging Drugs

16.1. Key Competitors

16.2. MicroLine Pilocarpine Ophthalmic): Eyenovia

16.2.1. Product Description

16.2.2. Other Developmental Activities

16.2.3. Clinical Development

16.2.4. Safety and Efficacy

16.2.5. Product Profile

16.2.6. Analysts’ Views

16.3. CSF-1 (PresbiDrops): Orasis Pharmaceuticals

16.3.1. Product Description

16.3.2. Other Developmental Activities

16.3.3. Clinical Development

16.3.4. Safety and Efficacy

16.3.5. Product Profile

16.3.6. Analysts’ Views

16.4. Nyxol: Ocuphire Pharma

16.4.1. Product Description

16.4.2. Other Developmental Activities

16.4.3. Clinical Development

16.4.4. Safety and Efficacy

16.4.5. Product Profile

16.4.6. Analysts’ Views

16.5. UNR844 (Lipoic Acid Choline Ester): Novartis

16.5.1. Product Description

16.5.2. Other Developmental Activities

16.5.3. Clinical Development

16.5.4. Safety and Efficacy

16.5.5. Product Profile

16.5.6. Analysts’ Views

16.6. VT-101 (Brimochol): Visus Therapeutics

16.6.1. Product Description

16.6.2. Other Developmental Activities

16.6.3. Clinical Development

16.6.4. Safety and Efficacy

16.6.5. Product Profile

16.6.6. Analysts’ Views

16.7. LNZ100 (Aceclidine 1.75%): LENZ Therapeutics

16.7.1. Product Description

16.7.2. Other Developmental Activities

16.7.3. Clinical Development

16.7.4. Safety and Efficacy

16.7.5. Product Profile

16.7.6. Analysts’ Views

16.8. GLK-302 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation

16.8.1. Product Description

16.8.2. Clinical Development

16.8.3. Product Profile

16.8.4. Analysts’ Views

16.9. AGN-241622: AbbVie

16.9.1. Product Description

16.9.2. Other Development Activity

16.9.3. Clinical Development

16.9.4. Product Profile

16.9.5. Analysts’ Views

17. Presbyopia: 7 Major Market Analysis

17.1. Key Findings

17.2. Market Outlook

17.3. Key Market Forecast Assumptions

17.4. Attribute Analysis of Prebyopia

17.5. 7MM Market Size

17.5.1. Total Market Size of Presbyopia in the 7MM

17.5.2. Market Size of Presbyopia by Therapies in the 7MM

17.6. The United States Market Size

17.6.1. Total Market Size of Presbyopia in the US

17.6.2. Market Size of Presbyopia by Therapies in the US

17.7. EU-5 Market Size

17.7.1. Germany

17.7.1.1. Total Market size of Presbyopia in Germany

17.7.1.2. Market Size of Presbyopia by Therapies in Germany

17.7.2. France

17.7.2.1. Total Market size of Presbyopia in France

17.7.2.2. Market Size of Presbyopia by Therapies in France

17.7.3. Italy

17.7.3.1. Total Market size of Presbyopia in Italy

17.7.3.2. Market Size of Presbyopia by Therapies in Italy

17.7.4. Spain

17.7.4.1. Total Market size of Presbyopia in Spain

17.7.4.2. Market Size of Presbyopia by Therapies in Spain

17.7.5. The United Kingdom

17.7.5.1. Total Market size of Presbyopia in the UK

17.7.5.2. Market Size of Presbyopia by Therapies in the UK

17.8. Japan

17.8.1. Total Market size of Presbyopia in Japan

17.8.2. Market Size of Presbyopia by Therapies in Japan

18. Market Access and Reimbursement

19. Key Opinion Leaders’ Views

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Unmet Needs

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

List of Table

Table 1: Summary of Presbyopia, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Key Events

Table 3: Common risk factors of presbyopia

Table 4: Recommended examination frequency for the pediatric patient

Table 5: Recommended examination frequency for the adult patient

Table 6: Prescribing Considerations for Presbyopia

Table 7: Comparison of the guidelines

Table 8: Total Prevalent Cases of Presbyopia in the 7MM (2019–2032)

Table 9: Total Diagnosed Cases of Presbyopia in the 7MM (2019–2032)

Table 10: Total Age-specific Cases of Presbyopia in the 7MM (2019–2032)

Table 11: Gender-specific Cases of Presbyopia in the 7MM (2019–2032)

Table 12: Severity-specific Cases of Presbyopia in the 7MM (2019–2032)

Table 13: Total Prevalent Cases of Presbyopia in the US (2019–2032)

Table 14: Total Diagnosed Cases of Presbyopia in the US (2019–2032)

Table 15: Total Age-specific Cases of Presbyopia in the US (2019–2032)

Table 16: Gender-specific Cases of Presbyopia in the US (2019–2032)

Table 17: Severity-specific Cases of Presbyopia in the US (2019–2032)

Table 18: Total Prevalent Cases of Presbyopia in Germany (2019–2032)

Table 19: Total Diagnosed Cases of Presbyopia in Germany (2019–2032)

Table 20: Total Age-specific Cases of Presbyopia in Germany (2019–2032)

Table 21: Gender-specific Cases of Presbyopia in Germany (2019–2032)

Table 22: Severity-specific Cases of Presbyopia in Germany (2019–2032)

Table 23: Total Prevalent Cases of Presbyopia in France (2019–2032)

Table 24: Total Diagnosed Cases of Presbyopia in France (2019–2032)

Table 25: Total Age-specific Cases of Presbyopia in France (2019–2032)

Table 26: Gender-specific Cases of Presbyopia in France (2019–2032)

Table 27: Severity-specific Cases of Presbyopia in France (2019–2032)

Table 28: Total Prevalent Cases of Presbyopia in Italy (2019–2032)

Table 29: Total Diagnosed Cases of Presbyopia in Italy (2019–2032)

Table 30: Total Age-specific Cases of Presbyopia in Italy (2019–2032)

Table 31: Gender-specific Cases of Presbyopia in Italy (2019–2032)

Table 32: Severity-specific Cases of Presbyopia in Italy (2019–2032)

Table 33: Total Prevalent Cases of Presbyopia in Spain (2019–2032)

Table 34: Total Diagnosed Cases of Presbyopia in Spain (2019–2032)

Table 35: Total Age-specific Cases of Presbyopia in Spain (2019–2032)

Table 36: Gender-specific Cases of Presbyopia in Spain (2019–2032)

Table 37: Severity-specific Cases of Presbyopia in Spain (2019–2032)

Table 38: Total Prevalent Cases of Presbyopia in the UK (2019–2032)

Table 39: Total Diagnosed Cases of Presbyopia in the UK (2019–2032)

Table 40: Total Age-specific Cases of Presbyopia in the UK (2019–2032)

Table 41: Gender-specific Cases of Presbyopia in the UK (2019–2032)

Table 42: Severity-specific Cases of Presbyopia in the UK (2019–2032)

Table 43: Total Prevalent Cases of Presbyopia in Japan (2019–2032)

Table 44: Total Diagnosed Cases of Presbyopia in Japan (2019–2032)

Table 45: Total Age-specific Cases of Presbyopia in Japan (2019–2032)

Table 46: Gender-specific Cases of Presbyopia in Japan (2019–2032)

Table 47: Severity-specific Cases of Presbyopia in Japan (2019–2032)

Table 48: Vuity (AGN-190584), Clinical Trial Description, 2022

Table 49: MicroLine (Pilocarpine Ophthalmic) Clinical Trial Description, 2022

Table 50: CSF-1 (PresbiDrops) Clinical Trial Description, 2022

Table 51: Nyxol and Pilocarpine: Clinical Trial Description, 2022

Table 52: UNR844 (Lipoic acid choline ester; formerly known as EV06)

Table 53: VT-101 (Brimochol), Clinical Trial Description, 2022

Table 54: LNZ100 (Aceclidine 1.75%): Clinical Trial Description, 2022

Table 55: GLK-302: Clinical Trial Description, 2022

Table 56: AGN-241622, Clinical Trial Description, 2022

Table 57: Key Market Forecast Assumptions for CSF-1

Table 58: Key Market Forecast Assumptions for UNR844

Table 59: Key Market Forecast Assumptions for MicroLine

Table 60: Key Market Forecast Assumptions for AGN-241622

Table 61: Key Market Forecast Assumptions for Nyxol + LDP

Table 62: Key Market Forecast Assumptions for VTI-001

Table 63: Key Market Forecast Assumptions for LNZ100/LNZ101

Table 64: 7MM Market Size of Presbyopia in USD Million (2019–2032)

Table 65: 7MM Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Table 66: The US Market Size of Presbyopia in USD Million (2019–2032)

Table 67: The US Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Table 68: Germany Market Size of Presbyopia in USD Million (2019–2032)

Table 69: Germany Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Table 70: France Market Size of Presbyopia in USD Million (2019–2032)

Table 71: France Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Table 72: Italy Market Size of Presbyopia in USD Million (2019–2032)

Table 73: Italy Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Table 74: Spain Market Size of Presbyopia in USD Million (2019–2032)

Table 75: Spain Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Table 76: The UK Market Size of Presbyopia in USD Million (2019–2032)

Table 77: The UK Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Table 78: Japan Market Size of Presbyopia in USD Million (2019–2032)

Table 79: Japan Market Size of Presbyopia by Therapies in USD Million (2019–2032)

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Presbyopia compared to a Normal eye

Figure 3: Symptoms of Presbyopia

Figure 4: Causes of Presbyopia

Figure 5: Anatomy of the eye

Figure 6: Pathogenesis of Presbyopia

Figure 7: Differential diagnosis of presbyopia

Figure 8: Treatment Algorithm

Figure 9: Management of Presbyopia

Figure 10: Optical correction with spectacle lenses

Figure 11: Optical correction with contact lenses

Figure 12: Conductive Keratoplasty

Figure 13: Total Prevalent Cases of Presbyopia in the 7MM (2019–2032)

Figure 14: Total Diagnosed Cases of Presbyopia in the 7MM (2019–2032)

Figure 15: Total Age-specific Cases of Presbyopia in the 7MM (2019–2032)

Figure 16: Gender-specific Cases of Presbyopia in the 7MM (2019–2032)

Figure 17: Severity-specific Cases of Presbyopia in the 7MM (2019–2032)

Figure 18: Total Prevalent Cases of Presbyopia in the US (2019–2032)

Figure 19: Total Diagnosed Cases of Presbyopia in the US (2019–2032)

Figure 20: Total Age-specific Cases of Presbyopia in the US (2019–2032)

Figure 21: Gender-specific Cases of Presbyopia in the US (2019–2032)

Figure 22: Severity-specific Cases of Presbyopia in the US (2019–2032)

Figure 23: Total Prevalent Cases of Presbyopia in Germany (2019–2032)

Figure 24: Total Diagnosed Cases of Presbyopia in Germany (2019–2032)

Figure 25: Total Age-specific Cases of Presbyopia in Germany (2019–2032)

Figure 26: Gender-specific Cases of Presbyopia in Germany (2019–2032)

Figure 27: Severity-specific Cases of Presbyopia in Germany (2019–2032)

Figure 28: Total Prevalent Cases of Presbyopia in France (2019–2032)

Figure 29: Total Diagnosed Cases of Presbyopia in France (2019–2032)

Figure 30: Total Age-specific Cases of Presbyopia in France (2019–2032)

Figure 31: Gender-specific Cases of Presbyopia in France (2019–2032)

Figure 32: Severity-specific Cases of Presbyopia in France (2019–2032)

Figure 33: Total Prevalent Cases of Presbyopia in Italy (2019–2032)

Figure 34: Total Diagnosed Cases of Presbyopia in Italy (2019–2032)

Figure 35: Total Age-specific Cases of Presbyopia in Italy (2019–2032)

Figure 36: Gender-specific Cases of Presbyopia in Italy (2019–2032)

Figure 37: Severity-specific Cases of Presbyopia in Italy (2019–2032)

Figure 38: Total Prevalent Cases of Presbyopia in Spain (2019–2032)

Figure 39: Total Diagnosed Cases of Presbyopia in Spain (2019–2032)

Figure 40: Total Age-specific Cases of Presbyopia in Spain (2019–2032)

Figure 41: Gender-specific Cases of Presbyopia in Spain (2019–2032)

Figure 42: Severity-specific Cases of Presbyopia in Spain (2019–2032)

Figure 43: Total Prevalent Cases of Presbyopia in the UK (2019–2032)

Figure 44: Total Diagnosed Cases of Presbyopia in the UK (2019–2032)

Figure 45: Total Age-specific Cases of Presbyopia in the UK (2019–2032)

Figure 46: Gender-specific Cases of Presbyopia in the UK (2019–2032)

Figure 47: Severity-specific Cases of Presbyopia in the UK (2019–2032)

Figure 48: Total Prevalent Cases of Presbyopia in Japan (2019–2032)

Figure 49: Total Diagnosed Cases of Presbyopia in Japan (2019–2032)

Figure 50: Total Age-specific Cases of Presbyopia in Japan (2019–2032)

Figure 51: Gender-specific Cases of Presbyopia in Japan (2019–2032)

Figure 52: Severity-specific Cases of Presbyopia in Japan (2019–2032)

Figure 53: Patient Journey

Figure 54: Market Size of Presbyopia in the 7MM, USD Million (2019–2032)

Figure 55: 7MM Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Figure 56: Market Size of Presbyopia in the US, USD Million (2019–2032)

Figure 57: The US Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Figure 58: Market Size of Presbyopia in Germany, USD Million (2019–2032)

Figure 59: Germany Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Figure 60: Market Size of Presbyopia in France, USD Million (2019–2032)

Figure 61: France Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Figure 62: Market Size of Presbyopia in Italy, USD Million (2019–2032)

Figure 63: Italy Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Figure 64: Market Size of Presbyopia in Spain, USD Million (2019–2032)

Figure 65: Spain Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Figure 66: Market Size of Presbyopia in the UK, USD Million (2019–2032)

Figure 67: The UK Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Figure 68: Market Size of Presbyopia in Japan, USD Million (2019–2032)

Figure 69: Japan Market Size of Presbyopia by Therapies in USD Million (2019–2032)

Figure 70: Market Drivers

Figure 71: Market Barriers

Figure 72: SWOT Analysis

Figure 73: Unmet Needs

AbbVie
Eyenovia
Orasis Pharmaceuticals
Novartis
Visus Therapeutics
LENZ Therapeutics
Glaukos Corporation
Ocuphire Pharma

 

Forward to Friend

Need A Quote